Background: The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that subcutaneous administration may be problematic. Objective: To investigate whether human subjects are sensitive to the effects of ghrelin administered by single subcutaneous injection. Study design: Randomized, double-blind, placebo-controlled trial. Subjects: Sixteen healthy lean volunteers (eight men and eight women). Protocol: Fasted subjects received subcutaneous injections of ghrelin (3.6 nmol/kg) or saline. After 30 min, a buffet breakfast was served. Results: Ghrelin injection increased energy intake by 27% (ghrelin 50767691 kJ versus saline 42307607 kJ, P ¼ 0.04). Ghrelin appeared to enhance the perceived palatability of the food offered (palatability score: ghrelin 81.173.6 versus saline 70.074.4; P ¼ 0.03). Conclusions: These results suggest that subcutaneous ghrelin is effective at stimulating energy intake and improving palatability and may be of direct use in the treatment of appetite loss.
Introduction
Loss of appetite and loss of weight are major causes of morbidity and mortality affecting many patients including those with cancer, HIV, cardiac cachexia, inflammatory conditions such as sepsis and burns and postoperative patients. 1 There is a need for effective and well-tolerated treatments to improve energy intake. We have recently reported that acute administration of intravenous ghrelin stimulates energy intake in cancer patients with loss of appetite. 2 However, intravenous administration is cumbersome and unsuited to outpatient clinical practice. A practical means of ghrelin delivery which retains bioactivity is required.
Ghrelin is a gastric hormone first identified as the endogenous ligand for the growth hormone secretagogue receptor. Ghrelin is a 28 amino-acid peptide, the active form of which has a novel post-translational addition of an octanoyl acyl group on the third residue. 3 Plasma ghrelin levels rise after fasting and fall after feeding. 4 In addition to stimulating growth hormone (GH) release, ghrelin increases food intake when administered peripherally in rodents and man. [5] [6] [7] Ghrelin has thus been postulated to act as a meal initiator. 4 Chronic ghrelin administration promotes adiposity and weight gain in rodents. 5, 6 Peptide hormones are not active when given orally due to digestion. Ghrelin is easily inactivated and subcutaneous ghrelin injection might result in inactivation due to loss of the acyl group. Although ghrelin has been administered subcutaneously to human subjects for evaluation of cardiac effects, the food intake response was not assessed. 8 We performed a double-blind, randomized, crossover trial in order to determine the effect of subcutaneous ghrelin on food intake in man.
Methods
The study was performed in accordance with the principles of the Declaration of Helsinki. All subjects gave their written informed consent to participate in the study. Synthetic human ghrelin was purchased from Bachem (Merseyside, UK). Peptide was dissolved in saline 0.9% (Bayer, Haywards Heath, UK) for subcutaneous administration.
In order to select a suitable dose of ghrelin, a pilot study was performed. The starting dose of ghrelin was 0.225 nmol/kg (equivalent to half ghrelin dose administered prior to the meal in our previous intravenous infusion study).
2 Doses were thereafter increased by a factor of two. No side effects were observed or reported at any dose of ghrelin administered. A trend for a consistent increase in food intake and an increase in GH release was observed at a dose of 3.6 nmol/kg (data not shown). We therefore proceeded to perform a double-blind, randomized, crossover trial in order to determine the effect of this dose of subcutaneous ghrelin on food intake. In total, 16 healthy volunteers (eight men and eight women) were recruited to the main study. . Fasted subjects attended on two mornings at least 2 days apart. At 0830 hours (t ¼ 0), they received a subcutaneous injection of ghrelin (3.6 nmol/kg) or saline. At 0900 hours (t ¼ 30), breakfast was served, comprising preweighed cake presented in excess, herbal tea or decaffeinated coffee and water. At 0930 hours (t ¼ 60), the remaining food was removed and weighed. During the study, subjects were asked to rate subjective hunger and nausea on 100 mm visual analogue scales (VAS) 9 at times À15, 0, 15, 30 and 60 min.
A 10 ml blood sample was also taken at each time point. Plasma for ghrelin assay (1 ml) was collected with 50 ml 1 M HCL and 10 ml 10 mg/ml phenyl methyl sulphonyl fluoride (PMSF). Intravenous ghrelin has been previously reported to lower blood pressure 10 and we were interested to determine whether subcutaneous ghrelin would have a similar effect. Therefore blood pressure and pulse were assessed at each time point. At t ¼ 60, subjects were asked to rate the pleasantness of the meal on a VAS. They were then allowed to go home and were asked to record their food intake for the rest of the day. Food diaries were assessed using Dietplan-5 nutritional software (Forestfield software Ltd, West Sussex, UK) by a dietician who was unaware of which treatment had been given. Plasma total ghrelin was measured by radioimmunoassay (RIA) using antiserum (SC-10368) from Santa Cruz Biotechnology (Delaware, California, USA).
11 Plasma-acylated ghrelin was quantified using the active ghrelin Linco RIA (product no GHRA-88HK). 12 In order to confirm the bioactivity of ghrelin administered subcutaneously, plasma GH was analysed with the Advantage automated chemiluminescent immunoassay (Nichols Institute Diagnostics). Subject characteristics (age and BMI) are presented as mean7standard deviation (s.d.). The results of the study are presented as mean7standard error of the mean (s.e.m.). The primary outcome of the study was energy intake at breakfast. Comparisons between ghrelin and saline injection days for energy intake, VAS and plasma levels were made using paired t-tests. We also examined and compared the effect of ghrelin on energy intake between the men and the women in the study using an unpaired t-test. In all cases, Po0.05 was considered to be statistically significant.
Results
Basal ghrelin levels were comparable on the saline and ghrelin injection days (total ghrelin 176716.3 and 192711.4 pmol/l respectively, P ¼ 0.1, acylated ghrelin levels 36.773.1 and 34.772.1 pmol/l respectively, P ¼ 0.7). The ratio of acylated to total basal ghrelin was approximately 1:5. Endogenous ghrelin decreased after breakfast on the saline injection day (total ghrelin fell from 198722.1 pmol/l immediately before breakfast to 161715.5 pmol/l 30 min after breakfast, Po0.05, and acylated ghrelin from 34.573.2 to 29.272.1 pmol/l, Po0.05). On the ghrelin day, total ghrelin peaked 15 min after injection at 988789.4 pmol/l. Acylated ghrelin peaked 30 min after injection at 355766.3 pmol/l (Figure 1 ). The ratio of acylated to total ghrelin following ghrelin injection was approximately 1:3. Subcutaneous ghrelin stimulated GH release confirming bioactivity. GH peaked at 30 min following ghrelin injection: saline day 5.671.7 mIU/l, ghrelin day 126718.3 mIU/l, Po0.05.
Energy intake at breakfast was increased by 27% following ghrelin injection (energy intake (kJ): saline 42307607, ghrelin 50767691, P ¼ 0.04) (Figure 2 ). There was no significant alteration in energy intake for the rest of the day following ghrelin injection (energy intake (kJ): saline day 66977860, ghrelin day 66307727, P ¼ 0.9). There were no significant differences in hunger scores between injections (mean score (mm) at 30 min: saline day 6976, ghrelin day 7275, P ¼ 0.5). However subjects found the meal more Ghrelin stimulates energy intake MR Druce et al pleasant following ghrelin injection (mean score (mm): ghrelin day 8174, saline day 7074, P ¼ 0.03). Subgroup analysis of the data revealed that the men ate more than the women on the saline control day (56197943 versus 28417378 kJ, Po0.05). However, similar percentage increases in food intake were observed following ghrelin injection in both sexes (% increase energy intake: men 23714%, women 30714%,
No side effects were reported by the subjects. There were no differences in the VAS nausea scores between infusion days (data not shown). After saline injection, the mean change in systolic blood pressure from basal to 30 min after injection was 0.971.9 mmHg to an absolute systolic pressure of 11772.7 mmHg. After ghrelin injection, the mean change was À5.472.8 to 10873.9 mmHg (Po0.05 versus saline day). No changes in diastolic pressure or pulse rate were observed following ghrelin injection (data not shown).
Discussion
Our results show that ghrelin increased food intake in healthy human volunteers following subcutaneous administration. Therefore, this practical route of administration has potential therapeutic benefits.
In our study, the ratio of acylated to total plasma ghrelin was similar on a saline day to that previously reported. 13 It was possible that significant breakdown of acylated to desacylated ghrelin would occur in the tissues following subcutaneous injection. Our finding that plasma-acylated ghrelin increased significantly following subcutaneous injection suggests that acylated ghrelin can reach the circulation via the subcutaneous route. The rise in GH observed is further evidence of the bioactivity of subcutaneous ghrelin. We also observed a small reduction in blood pressure as has previously been reported following intravenous ghrelin. 10 Plasma-acylated ghrelin levels had risen 15 min following subcutaneous injection and were similarly elevated at 30 min. This suggests that ghrelin injection 30 min before a meal might be the optimal time for stimulation of food intake. Millions of diabetics self-administer insulin in this way without difficulty. While direct comparison would not be valid because of differences in the administration route and subsequent timing of the meal, it is helpful to examine the feeding response following intravenous ghrelin in published work. Wren et al. 7 reported a 28% increase in food intake following a total intravenous dose of 1.4 nmol/kg. In our present study, we administered 3.6 nmol/kg subcutaneous ghrelin and observed a comparable 27% increase in food intake. We also observed an increase in the perceived palatability of the meal following ghrelin injection. An enhanced appreciation of the palatability of a meal could contribute to the increase in energy intake following ghrelin injection. Analysis of the food diaries of the current study revealed that, as with intravenous ghrelin, 2,7 the increase in food intake observed at the meal following subcutaneous ghrelin was not sustained for the rest of the day. However, there was no evidence of a subsequent reduction in energy intake to compensate for the increased food intake at the meal. The cake was selected to be given to the subjects for their breakfast because of its fixed nutrient components and because of the ease of reproducibility of measurement of energy intake between infusion days. Previous ghrelin studies have demonstrated similar increases in energy intake with a lunch-time meal. 2, 7 The energy intake on the saline injection day in the current study was relatively high with the men eating more than the women. Despite these high baselines, subcutaneous ghrelin significantly stimulated energy intake. The feeding response to ghrelin appeared to be similar in the men and women in the study. The effectiveness of subcutaneous administration of ghrelin on food intake can now lead to further trials in patients in whom anorexia is a significant impediment to recovery. Ghrelin stimulates energy intake MR Druce et al
